Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

References

• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997; 84: 223–43
   PubMedGoogle Scholar
• Walsh SJ, Rau LM. Autoimmune diseases: A leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000; 90: 1463–6
   PubMed Web of Science ®Google Scholar
• As found on product websites:. http://www.enbrel.com/?channel=GOSEA&=SENC,, http://www.remicade.com/remicade/global/index.html, , and. http://www.humira.com/ . Accessed 15 August 2007
   Google Scholar
• Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J. 2005; 98: 192–204
   PubMedGoogle Scholar
• Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, for the Etanercept Psoriasis Study Group, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349: 2014–22
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: A randomised trial. Lancet. 2001; 357: 1842–7
   PubMed Web of Science ®Google Scholar
• Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000; 42: 829–30
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med. 2002; 346: 1349–56
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334: 1717–25
   PubMed Web of Science ®Google Scholar
• Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, Mccloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43: 38–47
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121: 1088–94
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet. 2002; 359: 1187–93
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346: 1349–56
   PubMed Web of Science ®Google Scholar
• Braughman RPI, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001; 118: 70–4
   Google Scholar
• Tan MH, Gordon M, Lebwohl O, George J, Lebwohl M. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001; 137: 930–3
   PubMed Web of Science ®Google Scholar
• Richlin C. Newer therapeutic approaches: Spondyloarthritis and uveitis. Rheum Dis Clin North Am. 2006; 32: 75–90
   PubMedGoogle Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behcet disease. Ann Intern Med. 2004; 140: 404–6
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: Use of targeted immunotherapeutics as pathogenic probes. Lupus. 2003; 12: 190–4
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley L, Baker D. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003; 48: 829–35
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139: 1627–32
   PubMed Web of Science ®Google Scholar
• Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther. 2005; 7: R666–76
   PubMed Web of Science ®Google Scholar
• Baeten D, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defense in the pathogenesis of the disease?. Ann Rheum Dis. 2003; 62: 829–34
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect?. J Rheumatol. 2007; 34: 434–7
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007; 156: 486–91
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum. 2005; 52: 2513–18
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Pyrpasopoulou A, Leontsini M, Zamboulis C. Anti-TNF-alpha-induced psoriasis: Case report of an unusual adverse event. Int J Dermatol. 2006; 45: 982–3
   PubMed Web of Science ®Google Scholar
• Matthews C, Rogers S, Fitzgerald O. Development of new-onset psoriasis while on anti-TNFα treatment. Ann Rheum Dis. 2006; 65: 1529–30
   PubMedGoogle Scholar
• Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor alpha antagonist therapy: A case series. J Rheumatol. 2007; 34: 380–5
   PubMed Web of Science ®Google Scholar
• Seneschal J, Heliot-hosten I, Bouysou-gauthier ML, et al. Eruption psoriasiforme sous anti-TNF alpha: Un mecanisme toxidermique? [abstract]. Rev Rhum. 2005; 72: 1009
   Google Scholar
• Kary S, Worm M, Fritz J, et al. New onset of aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNF-alpha antagonists: Report of 8 cases [abstract]. Ann Rheum Dis. 2004; 63((suppl))276
   Google Scholar
• Haibel H, Spiller I, Strasser C. Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents [abstract]. Ann Rheum Dis. 2004; 63((suppl))405
   Google Scholar
• Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: Two cases. Br J Dermatol. 2004; 151: 506–7
   PubMedGoogle Scholar
• Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: Comment on the article by Beuthien, et al. Arthritis Rheum. 2005; 52: 1333–4
   PubMedGoogle Scholar
• Starmans-kool MJ, Peeters HR, Houben HH. Pustular skin lesions in patients treated with infliximab: Report of two cases. Rheumatol Int. 2005; 25: 550–2
   PubMedGoogle Scholar
• Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005; 30: 713–14
   PubMedGoogle Scholar
• Adams DR, Buckel T, Sceppa JA. Infliximab-associated new-onset psoriasis. J Drugs Dermatol. 2006; 5: 178–9
   PubMedGoogle Scholar
• Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004; 38: 54–7
   PubMed Web of Science ®Google Scholar
• Peek R, Scott-jupp R, Strike H, Clinch J, Ramanan AV. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006; 65: 1259
   PubMed Web of Science ®Google Scholar
• Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy. Eur J Dermatol. 2006; 16: 316–17
   PubMedGoogle Scholar
• Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview. Dermatology. 2006; 213: 182–6
   PubMedGoogle Scholar
• Goiriz R, Daudén E, Pérez-gala S, Guhl G, García-díez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007; 32: 176–9
   PubMed Web of Science ®Google Scholar
• Ubriani R, Van Voorhees AS. Onset of psoriasis during treatment with TNF-α antagonists: A report of 3 cases. Arch Dermatol. 2007; 143: 270–2
   PubMedGoogle Scholar
• Takahashi H, Hashimoto Y, Ishida-Yamamoto I, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007; 34: 468–72
   PubMed Web of Science ®Google Scholar
• Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol. 2006; 33: 1411–14
   PubMed Web of Science ®Google Scholar
• Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: A case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008; 22: 380–2
   PubMedGoogle Scholar
• Martínez-morán C, Sanz-muñoz C, Morales-callaghan AM, Torrero V, Miranda-Romero A. Pustular psoriasis induced by infliximab. J Eur Acad Dermatol. 2007; 21: 1424–6
   Google Scholar
• Beuthien WMellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004; 50: 1690–2
   PubMed Web of Science ®Google Scholar
• Djennane S, Oro S, Lévy-weil FE, Sigal M, Feldman JL. Psoriasis cutané induit par traitement anti-TNF alpha au cours d'une fasciite éosinophile [abstract]. Rev Rhum. 2005; 72: 10–1
   Google Scholar
• Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford). 2006; 45: 730–3
   PubMed Web of Science ®Google Scholar
• Goncalves DP, Laurindo I, Scheinberg MA. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol. 2006; 12: 262
   PubMedGoogle Scholar
• Richette P, Viguier M, Bachelez H, Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: A class effect?. J Rheumatol. 2007; 34: 438
   PubMed Web of Science ®Google Scholar
• Zarnitsky C, Bravard P, Godon J, Alcaix D. Pustulose palmaire et plantaire chez une patiente traitée par adalimumab. Rev Rhum. 2005; 72: 1195
   Google Scholar
• Umeno J, Matsumoto T, Jo Y, Ichikawa M, Urabe K, Iida M. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1188–9
   PubMedGoogle Scholar
• Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli C. Another paradox in Crohn's disease: New onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis. 2007; 13: 1059–61
   PubMedGoogle Scholar
• Heymann WR. Tumor necrosis factor inhibitor-induced pustular psoriasis?. J Am Acad Dermatol. 2007; 56: 327–9
   PubMedGoogle Scholar
• deGannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatic conditions. Arch Dermatol. 2007; 143: 223–31
   PubMedGoogle Scholar
• Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004; 3: 439–40
   PubMedGoogle Scholar
• Michaelsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006; 54: 737–8
   PubMed Web of Science ®Google Scholar
• Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006; 65: 405–7
   PubMedGoogle Scholar
• Cavailhes A, Ingen-housz-oro S, Djennane S, Rafaa M, Fiszenson-albala F, Weber N, et al. Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab. Ann Dermatol Venereol. 2007; 134((4 Pt 1))363–7
   PubMedGoogle Scholar
• Chustecka Z. Psoriasis with TNF inhibitors: Is there an infectious etiology?. 2007, Accessed July 29. URL: http://www.jointandbone.org/viewArticle.do?primaryKey=569511
   Google Scholar
• Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept?. Clin Infect Dis. 2005; 41: S199–203
   PubMed Web of Science ®Google Scholar
• Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: A case series. BMC Dermatol. 2007; 7: 2
   PubMedGoogle Scholar
• Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Efalizumab-associated papular psoriasis. Arch Dermatol. 2007; 143: 900–6
   PubMedGoogle Scholar
• Herron M, Kinckley M, Hoffman M, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005; 141: 1527–34
   PubMed Web of Science ®Google Scholar
• Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008; 22: 392–3
   PubMedGoogle Scholar
• Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: A clinical and immunohistological study. Br J Dermatol. 1998; 138: 390–8
   PubMed Web of Science ®Google Scholar
• Hagforsen E, Nordlind K, Michaelsson G. Skin nerve fibres and their contacts with mast cells in patients with palmoplantar pustulosis. Arch Dermatol Res. 2000; 292: 269–74
   PubMedGoogle Scholar
• Niizeki H, Naruse T, Hashigucci K, Yokoyama M, Yamasaki Y, Akiya K, et al. Polymorphism in the TNFA promoter region gene is not associated with palmoplantar pustulosis. Tissue Antigens. 2000; 56: 162–5
   PubMedGoogle Scholar
• Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997; 109: 562–5
   PubMed Web of Science ®Google Scholar
• Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?. Br J Dermatol. 2005; 153: 1243–4
   PubMed Web of Science ®Google Scholar
• Van der Fits L, Van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon alpha sensitivity is unaltered. J Invest Dermatol. 2004; 122: 51–60
   PubMed Web of Science ®Google Scholar
• Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol. 2005; 125: 936–44
   PubMed Web of Science ®Google Scholar
• Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003; 200: 255–68
   Google Scholar
• Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: An emerging role for interferon alpha. J Invest Dermatol. 2005; 125: xiv–xv
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFNalpha in autoimmune disease. Proc Natl Acad Sci U S A. 2005; 102: 3372–7
   PubMed Web of Science ®Google Scholar
• Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005; 44: 172–5
   PubMed Web of Science ®Google Scholar
• Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, et al. CD8+ T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity. 2000; 13: 643–55
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005; 202: 135–43
   PubMed Web of Science ®Google Scholar
• Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist Imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140: 1490–5
   PubMed Web of Science ®Google Scholar
• Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005; 4: 221–2
   PubMedGoogle Scholar
• Saissi EH, Beau-Salinas F, Jonville-Béra AP, Lorette G, Autret-Leca E, et al. Centres Régionaux de Pharmacovigilance. [Drugs associated with acute generalized exanthematic pustulosis.]. Ann Dermatol Venereol. 2003; 130: 612–18
   PubMed Web of Science ®Google Scholar
• Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: Is it pustular psoriasis or a pustular drug eruption?. Br J Dermatol. 1994; 130: 514–19
   PubMedGoogle Scholar
• Carter JD. Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists. Ann Rheum Dis. 2006; 65: 1680
   PubMedGoogle Scholar
• Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343(15)941–602
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002; 359: 1541–9
   PubMed Web of Science ®Google Scholar
• Sakai T, Kawaguchi M, Ishizawa S, Kaji T, Kitagawa K, Koizumi F. Histological features of palatine tonsils in pustulosis palmaris and plantaris: A morphometric study. Pathol Int. 1994; 44: 186–93
   PubMedGoogle Scholar
• Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K. Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: Relation to focal infection and response to treatments. J Dermatol Sci. 1995; 10: 8–15
   PubMedGoogle Scholar
• Sfikakis PP, Kollias G. Tumor necrosis factor in experimental and clinical arthritis. Curr Opin Rheumatol. 2003; 15: 380–6
   PubMed Web of Science ®Google Scholar
• Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med. 1991; 174: 1461–6
   PubMed Web of Science ®Google Scholar